功能纳米与软物质研究院学术报告

CNRS, Institut de Biologie Moléculaire et Cellulaire, Laboratoire d’Immunopathologie et Chimie Thérapeutique, 15, Rue René Descartes, 67084 Strasbourg, France

题目:  Chemical modifications and cellular impact of graphene oxide

时间：7月7日（星期一）上午9:00

地点：独墅湖校区909号楼B会议室

摘要：

Graphene is considered the future revolutionary material, being part of a bigger family that has been identified as the graphene related materials. Graphene oxide (GO) is one of the member of this carbon family and it is gaining tremendous interest in fields such as energy storage, catalysis and biomedicine. Clarifying the existence of multiple graphene forms allows to better understanding the differences between the components and eventually correlating their biological effects to the physico-chemical characteristics of each structure. GO is also offering the possibility of chemical functionalization that allows exploiting this platform for many applications. In addition, as for other nanomaterials, the intense research activity on potential applications of graphene imperatively needs to be associated to the assessment of the safety profile. In this presentation, we will describe the chemical reactivity of GO, the effects on human primary cells and the modifications that can be introduced in view of future biomedical applications.

个人简介：

Alberto Bianco received his “Laurea” (Master) degree in Chemistry in 1992 and his PhD in 1995 from the University of Padova (Italy), under the supervision of Professor Claudio Toniolo. As a visiting scientist, he worked at the University of Lausanne during 1992 (with Professor Manfred Mutter), at the University of Tübingen in 1996?1997 (with Professor Günther Jung, as an Alexander von Humboldt fellow) and at the University of Padova in 1997?1998 (with Professor Gianfranco Scorrano). He is currently Research Director at the CNRS in Strasbourg (France). His research interests focus on the design and functionalisation of carbon-based nanomaterials (carbon nanotubes, graphene and adamantane) and their use for therapeutic, diagnostic and imaging applications; the development of functionalised carbon nanotubes and graphene in nanomedicine and the study of their impact on health and environment; and the design of adamantane-based dendrimers for drug delivery. He is author and co-author of over 185 papers. He is member of the American Chemical Society, the French Group of Peptides and Proteins, and the European Peptide Society. He is also in the Advisory Board of Nanomedicine (Lond.), Nanotechnology Reviews and the Journal of Peptide Science. In 2011 he has been appointed as Editor of Carbon.